SI3478713T1 - Sestavki za zdravljenje amiloidoze - Google Patents

Sestavki za zdravljenje amiloidoze

Info

Publication number
SI3478713T1
SI3478713T1 SI201731146T SI201731146T SI3478713T1 SI 3478713 T1 SI3478713 T1 SI 3478713T1 SI 201731146 T SI201731146 T SI 201731146T SI 201731146 T SI201731146 T SI 201731146T SI 3478713 T1 SI3478713 T1 SI 3478713T1
Authority
SI
Slovenia
Prior art keywords
compositions
treating amyloidosis
amyloidosis
treating
Prior art date
Application number
SI201731146T
Other languages
English (en)
Slovenian (sl)
Inventor
Gene G. Kinney
Spencer D. GUTHRIE
Martin Koller
Original Assignee
Prothena Biosciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Limited filed Critical Prothena Biosciences Limited
Publication of SI3478713T1 publication Critical patent/SI3478713T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201731146T 2016-06-30 2017-06-30 Sestavki za zdravljenje amiloidoze SI3478713T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357151P 2016-06-30 2016-06-30
PCT/US2017/040289 WO2018005967A1 (en) 2016-06-30 2017-06-30 Compositions for treating amyloidosis
EP17740200.5A EP3478713B1 (en) 2016-06-30 2017-06-30 Compositions for treating amyloidosis

Publications (1)

Publication Number Publication Date
SI3478713T1 true SI3478713T1 (sl) 2022-06-30

Family

ID=59351103

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731146T SI3478713T1 (sl) 2016-06-30 2017-06-30 Sestavki za zdravljenje amiloidoze

Country Status (16)

Country Link
US (2) US20190169280A1 (enExample)
EP (1) EP3478713B1 (enExample)
JP (3) JP2019519584A (enExample)
CY (1) CY1125536T1 (enExample)
DK (1) DK3478713T3 (enExample)
ES (1) ES2914781T3 (enExample)
HR (1) HRP20220979T8 (enExample)
HU (1) HUE059400T2 (enExample)
LT (1) LT3478713T (enExample)
MA (1) MA45552A (enExample)
PL (1) PL3478713T3 (enExample)
PT (1) PT3478713T (enExample)
RS (1) RS63446B1 (enExample)
SI (1) SI3478713T1 (enExample)
SM (1) SMT202200261T1 (enExample)
WO (1) WO2018005967A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092264A1 (ru) * 2018-03-23 2020-12-03 Протена Байосайенсиз Лимитед Лечение и профилактика амилоидоза
EP3923954A1 (en) * 2019-02-12 2021-12-22 Prothena Biosciences Limited Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells
PH12021552135A1 (en) * 2019-03-05 2022-08-31 Prothena Biosciences Ltd Methods of treating al amyloidosis
EP4022062A1 (en) * 2019-08-30 2022-07-06 Alnylam Pharmaceuticals, Inc. Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy
MX2022016544A (es) * 2020-06-22 2023-04-05 Ngm Biopharmaceuticals Inc Agentes de union a lair-1 y metodos para su uso.
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
EA028356B1 (ru) 2007-12-28 2017-11-30 Протена Байосайенсиз Лимитед Лечение и профилактика амилоидоза
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods

Also Published As

Publication number Publication date
HRP20220979T8 (hr) 2023-02-03
LT3478713T (lt) 2022-06-10
CY1125536T1 (el) 2025-05-09
ES2914781T3 (es) 2022-06-16
EP3478713A1 (en) 2019-05-08
EP3478713B1 (en) 2022-05-11
WO2018005967A1 (en) 2018-01-04
PL3478713T3 (pl) 2022-10-10
JP2019519584A (ja) 2019-07-11
RS63446B1 (sr) 2022-08-31
HRP20220979T1 (hr) 2022-11-11
MA45552A (fr) 2019-05-08
JP2024127990A (ja) 2024-09-20
PT3478713T (pt) 2022-05-27
US20190169280A1 (en) 2019-06-06
SMT202200261T1 (it) 2022-07-21
DK3478713T3 (da) 2022-06-20
JP2022121658A (ja) 2022-08-19
US20210079078A1 (en) 2021-03-18
HUE059400T2 (hu) 2022-11-28

Similar Documents

Publication Publication Date Title
IL261792B (en) Preparations
GB201715639D0 (en) Compositions for wound treatment
IL260933A (en) Preparations containing tocorsol or its analogues
GB201610156D0 (en) Cliptac compositions
SMT202200370T1 (it) Composizione per il trattamento del cancro
LT3478713T (lt) Kompozicijos, skirtos amiloidozės gydymui
GB201600075D0 (en) Immunogenci composition
ES3049062T3 (en) Compositions
GB201614799D0 (en) Compositions
GB201610628D0 (en) New compositions
SMT202300229T1 (it) Composizioni per trattare condizioni oftalmiche
GB201602658D0 (en) Compositions
GB201602579D0 (en) New compositions
IL246919A0 (en) New preparations for the treatment of mechanical nerve injuries
IL268715A (en) Preparations for the treatment of acne
HK40008815A (en) Compositions for treating amyloidosis
GB201510658D0 (en) Compositions for wound treatment
GB201614230D0 (en) Compositions
GB201611960D0 (en) Compositions
GB201611851D0 (en) Compositions
GB201602656D0 (en) Compositions
GB201604899D0 (en) Composition
GB201604902D0 (en) Composition
GB201604901D0 (en) Composition
GB201604905D0 (en) Composition